Your browser doesn't support javascript.
loading
Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1).
Simon, James A; Anderson, Richard A; Ballantyne, Elizabeth; Bolognese, James; Caetano, Cecilia; Joffe, Hadine; Kerr, Mary; Panay, Nick; Seitz, Christian; Seymore, Susan; Trower, Mike; Zuurman, Lineke; Pawsey, Steve.
Afiliación
  • Simon JA; From the George Washington University, IntimMedicine Specialists, Washington, DC.
  • Anderson RA; MRC Centre for Reproductive Health, Queens Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom.
  • Ballantyne E; NeRRe Therapeutics, Stevenage, United Kingdom.
  • Bolognese J; Cytel, Waltham, MA.
  • Caetano C; Bayer CC AG, Basel, Switzerland.
  • Joffe H; Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
  • Kerr M; NeRRe Therapeutics, Stevenage, United Kingdom.
  • Panay N; Queen Charlotte's and Chelsea and Westminster Hospitals, Imperial College, London, United Kingdom.
  • Seitz C; Bayer AG, Berlin, Germany.
  • Seymore S; NeRRe Therapeutics, Stevenage, United Kingdom.
  • Trower M; NeRRe Therapeutics, Stevenage, United Kingdom.
  • Zuurman L; Bayer CC AG, Basel, Switzerland.
  • Pawsey S; NeRRe Therapeutics, Stevenage, United Kingdom.
Menopause ; 30(3): 239-246, 2023 03 01.
Article en En | MEDLINE | ID: mdl-36720081
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Calidad de Vida / Sofocos Tipo de estudio: Clinical_trials / Diagnostic_studies Límite: Female / Humans Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Calidad de Vida / Sofocos Tipo de estudio: Clinical_trials / Diagnostic_studies Límite: Female / Humans Idioma: En Año: 2023 Tipo del documento: Article